A Multi-Center Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy 12 subjects with pediatric MS
Age
5–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages Eligible for Study: 5 Years to 17 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No Criteria
Subject is between 5 and 17 years of age, inclusive
Clinically diagnosed Pediatric MS
Definite Pediatric MS by the revised McDonald criteria (2005) (Appendix A), with a pediatric MS course
Expanded Disability Status Scale (EDSS) \<= score 6.5 (Appendix B) Two or more documented clinical relapses of MS in the preceding 24 months OR one documented clinical relapse of MS in the preceding 12 months prior to screening
